Metrics Inc. Names Tom Salus Director of Sales

Greenville, NC, August 22, 2013 --(PR.com)-- Metrics Inc. has appointed Tom Salus as its director of sales.

In his new role, Salus will identify and expand new business opportunities with current and potential clients and manage the company’s field sales force.

Salus brings to Metrics more than 20 years of professional experience in the pharmaceutical contract development and manufacturing industry.

Most recently, Salus served as associate vice president of business development and contract services for Wockhardt Ltd. Wockhardt is a global pharmaceutical and biotechnology company with multi-disciplinary and innovative research and development programs, and a generic pharmaceutical product portfolio of more than 257 unique national drug codes spanning 66 different product families.

Prior to that, Salus worked for seven years as director of pharmaceutical business development for Glatt Air Techniques Inc., where he focused on the licensing, contract manufacturing and development of proprietary and generic oral solid dosage forms and controlled release products.

Salus first entered the pharmaceutical industry as an analytical research and development chemist for Greenwich Pharmaceutical Inc., for which he developed and validated analytical methods for new chemical entities and maintained cGMP and cGLP compliance. He holds a bachelor’s of science degree in forensic chemistry from West Chester University.

Metrics Inc. is a full-service global pharmaceutical development and manufacturing organization serving clients worldwide. We deliver proven scientific and operational excellence for solid oral dosage forms.

Their company’s areas of expertise include quality pharmaceutical formulation development; first-time-in-man (FTIM) formulations; clinical trial material (CTM) manufacturing for Phase I, II and III trials; and analytical method development and validation services leading to commercial scale manufacturing.

Within the past five years, Metrics has conducted more than 75 FTIM studies while simultaneously producing 700-plus batches of CTM.

Metrics’ technical capabilities include highly potent, cytotoxic and unstable compounds, Schedule II-V controlled substances, and products with poor bioequivalence – for which we offer an impressive proprietary portfolio of advanced delivery methods.

Their work supports investigational new drug (IND), new drug (NDA) and abbreviated new drug (ANDA) submissions made to worldwide regulatory agencies on behalf of clients ranging from internationally renowned corporations to small virtual companies.

Based in Greenville, N.C., Metrics Inc. proudly operates as a subsidiary of Mayne Pharma Group Limited. Learn more at metrics inc dot com.